Updates are available Correction dated 2019-01-31
Click to view Correction: https://doi.org/10.1007/s40265-019-1063-2
Updates are available Correction dated 2019-03-13
Click to view Correction: https://doi.org/10.1007/s40265-019-01094-0
-
Authors
- License Information
-
More Information
Article History
First Online: 8 January 2019
Change Date: 31 January 2019
Change Type: Correction
Change Date: 13 March 2019
Change Type: Correction
Change Type: Correction
Change Details: Page 7, Section 4.1, third paragraph, which previously read:
Change Details: In several sections of this review article, insulin degludec U100 has been incorrectly referred to as a highly concentrated basal insulin. Although data for both the U100 and U200 formulations of insulin degludec are presented, only insulin degludec U200 and insulin glargine U300 should be referred to as highly concentrated basal insulins.
Change Date: 13 March 2019
Change Details: In several sections of this review article, insulin degludec U100 has been incorrectly referred to as a highly concentrated basal insulin. Although data for both the U100 and U200 formulations of insulin degludec are presented, only insulin degludec U200 and insulin glargine U300 should be referred to as highly concentrated basal insulins.
Compliance with Ethical Standards
:
: SC has received speaker fees or educational funding, or both, from Janssen, Eli Lilly, Novo Nordisk, AstraZeneca, and Boehringer Ingelheim and grants in support of investigator initiated trials from Boehringer Ingelheim and Janssen. KK has acted as a consultant and speaker for AstraZeneca, Novartis, Novo Nordisk, Sanofi-Aventis, Lilly, Merck Sharp & Dohme, Janssen, and Boehringer Ingelheim, has received grants in support of investigator and investigator-initiated trials from AstraZeneca, Novartis, Novo Nordisk, Sanofi-Aventis, Lilly, Boehringer Ingelheim, Merck Sharp & Dohme, and Roche, and has served on advisory boards for AstraZeneca, Novartis, Novo Nordisk, Sanofi-Aventis, Lilly, Merck Sharp & Dohme, Janssen, and Boehringher Ingelheim. MJD reports personal fees from Novo Nordisk, Sanofi-Aventis, Eli Lilly, Merck Sharp & Dohme, Boehringer Ingelheim, AstraZeneca, Janssen, Mitsubishi Tanabe Pharma Corporation, and Takeda Pharmaceuticals International and grants from Novo Nordisk, Sanofi- Aventis, Eli Lilly, Boehringer Ingelheim, and Janssen.
